No Data
No Data
No Data
No Data
No Data
GSK Invests in BioVersys to Speed Development of Potential Tuberculosis Treatment
GSK (GSK) and BioVersys have expanded their collaboration to speed up development of alpibectir, a potential tuberculosis treatment, BioVersys said Tuesday. As part of the deal, GSK will take a 12.3 m
MT Newswires17:51
BioVersys And GSK Boost Fight Against Tuberculosis With Expanded Partnership And Series C Funding Increase By CHF 12.3M
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C fina
Benzinga14:18
GSK Plc (NYSE:GSK) Q1 2024 Earnings Call Transcript
Yahoo FinanceMay 5 20:44
Research Alert: CFRA Keeps Hold Opinion On Adss Of Gsk Plc
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our target price by USD5 to US
MT NewswiresMay 2 13:10
GSK PLC To Go Ex-Dividend On May 16th, 2024 With 0.18869 USD Dividend Per Share
May 2nd - $GSK PLC(GLAXF.US)$ is trading ex-dividend on May 16th, 2024. Shareholders of record on May 17th, 2024 will receive 0.188 USD dividend per share on July 11th, 2024. The ex-dividend date
Futu NewsMay 2 07:45
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0921 ET - GSK's CEO Emma Walmsley says in a press call that sh
WSJMay 2 00:20
No Data
No Data